Peripheral artery disease. Part 2: Medical and endovascular treatment

Nature Reviews Cardiology

Volumn 8, Issue 8, 2011, Pages 429-441

  Weinberg, Mitchell D ^a   Lau, Joe F ^a   Rosenfield, Kenneth ^b   Olin, Jeffrey W ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 INHIBITOR; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; MILRINONE; NAFTIDROFURYL; OMEPRAZOLE; PACLITAXEL; PENTOXIFYLLINE; PERINDOPRIL; PIPERANOMETOZINE; PLACEBO; PRASUGREL; RAMIPRIL; RAPAMYCIN; SIMVASTATIN; TICAGRELOR; TICLOPIDINE; VORAPAXAR; WARFARIN;

ACUTE CORONARY SYNDROME; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BARE METAL STENT; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PROCEDURES; CEREBROVASCULAR DISEASE; CLAUDICATION; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DIABETES CONTROL; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG ELUTING STENT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOVASCULAR SURGERY; ENDOVASCULAR TREATMENT; GLYCEMIC CONTROL; GRAFT PATENCY; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; ILIAC ARTERY DISEASE; IN-STENT RESTENOSIS; INFRAINGUINAL ARTERY DISEASE; INFRAPOPLITEAL ARTERY DISEASE; INTERMETHOD COMPARISON; INTERMITTENT CLAUDICATION; KINESIOTHERAPY; LIFESTYLE; LIMB ISCHEMIA; LOOSE FECES; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PATIENT COUNSELING; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; REVIEW; RISK REDUCTION; SMOKING CESSATION; SMOKING CESSATION PROGRAM; STENT; STROKE; TRANSIENT ISCHEMIC ATTACK;

CARDIOVASCULAR AGENTS; ENDOVASCULAR PROCEDURES; EXERCISE THERAPY; HUMANS; PERIPHERAL ARTERIAL DISEASE; PREVENTIVE HEALTH SERVICES; RISK ASSESSMENT; RISK FACTORS; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 79960940789     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2011.81     Document Type: Review

References (126)

1. Lau, J. F., Weinberg, M. D. & Olin, J. W. Peripheral artery disease. Part 1: clinical evaluation and noninvasive diagnosis. Nat. Rev. Cardiol. doi:101038/nrcardio.201166
2. Criqui, M. H. Peripheral arterial disease-epidemiological aspects. Vasc. Med. 6, 3-7 (2001).
3. Hobbs, S. D. & Bradbury, A. W. Smoking cessation strategies in patients with peripheral arterial disease: an evidence-based approach. Eur. J. Vasc. Endovasc. Surg. 26, 341-347 (2003). (Pubitemid 37266140)
4. Jonason, T. & Bergstrom, R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med. Scand. 221, 253-260 (1987). (Pubitemid 17069424)
5. Faulkner, K. W., House, A. K. & Castleden, W. M. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med. J. Aust. 1, 217-219 (1983). (Pubitemid 13093285)
6. Quick, C. R. & Cotton, L. T. The measured effect of stopping smoking on intermittent claudication. Br. J. Surg. 69 (Suppl.), S24-S26 (1982). (Pubitemid 12096147)
7. Olin, J. W. et al. ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on performance measures, the American College of Radiology, the Society for Cardiac Angiography and Interventions, the Society for Interventional Radiology, the Society for Vascular Medicine, the Society for Vascular Nursing, and the Society for Vascular Surgery (Writing Committee to Develop Clinical Performance Measures for Peripheral Artery Disease).Circulation 122, 2583-2618 (2010).
8. Jorenby, D. E. et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 340, 685-691 (1999). (Pubitemid 29110752)
9. Cahill, K., Stead, L. F. & Lancaster, T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews, Issue 2 Art. No.: CD006103 doi: 101002/14651858CD006103pub5 (2011).
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).JAMA 285, 2486-2497 (2001).
11. The Scandinavian Simvastatin Survival Study (4S) investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet 344, 1383-1389 (1994).
12. Sacks, F. M. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335, 1001-1009 (1996). (Pubitemid 26338729)
13. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339, 1349-1357 (1998).
14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
15. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J. Vasc. Surg. 45, 645-654 (2007).
16. Giri, J. et al. Statin use and functional decline in patients with and without peripheral arterial disease. J. Am. Coll. Cardiol. 47, 998-1004 (2006).
17. Hirsch, A. T. et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J. Am. Coll. Cardiol. 47, 1239-1312 (2006).
18. Chobanian, A. V. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289, 2560-2572 (2003). (Pubitemid 37430158)
19. Cushman, W. C. et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575-1585 (2010).
20. Cooper-DeHoff, R. M. et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304, 61-68 (2010).
21. Olin, J. W. Hypertension and peripheral arterial disease. Vasc. Med. 10, 241-246 (2005). (Pubitemid 41479683)
22. Clement, D. L. Treatment of hypertension in patients with peripheral arterial disease: an update. Curr. Hypertens. Rep. 11, 271-276 (2009).
23. Yusuf, S. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145-153 (2000). (Pubitemid 30051645)
24. Fox, K. M. for the EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).Lancet 362, 782-788 (2003). (Pubitemid 37093919)
25. Radack, K. & Deck, C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch. Intern. Med. 151, 1769-1776 (1991).
26. Moritz, T., Duckworth, W. & Abraira, C. Veterans Affairs diabetes trial-corrections. N. Engl. J. Med. 361, 1024-1025 (2009).
27. Patel, A. et al. for the ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560-2572 (2008). (Pubitemid 351831357)
28. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).Lancet 352, 837-853 (1998).
29. Gerstein, H. C. et al. for the Action to Control Cardiovascular Risk in Diabetes Study Group, Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008). (Pubitemid 351831356)
30. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 26, 3333-3341 (2003).
31. Bazzano, L. A., Reynolds, K., Holder, K. N. & He, J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 296, 2720-2726 (2006). (Pubitemid 44917549)
32. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71-86 (2002).
33. Sobel, M. & Verhaeghe, R. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest 133, 815S-843S (2008).
34. Norgren, L. et al. for the TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).J. Vasc. Surg. 45 (Suppl. S), S5-S67 (2007). (Pubitemid 46151680)
35. Baigent, C. et al. for the Antithrombotic Trialists' (ATT) Collaboration, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849-1860 (2009).
36. Berger, J. S., Krantz, M. J., Kittelson, J. M. & Hiatt, W. R. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 301, 1909-1919 (2009).
37. Fowkes, F. G. et al. for the Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303, 841-848 (2010).
38. Belch, J. et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337, a1840 (2008).
39. Janzon, L. et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J. Intern. Med. 227, 301-308 (1990).
40. Bergqvist, D., Almgren, B. & Dickinson, J. P. Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentre Study (STIMS).Eur. J. Vasc. Endovasc. Surg. 10, 69-76 (1995).
41. Hiatt, W. R. Medical treatment of peripheral arterial disease and claudication. N. Engl. J. Med. 344, 1608-1621 (2001). (Pubitemid 32479915)
42. Hiatt, W. R. & Krantz, M. J. Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudication. Vasc. Med. 11, 55-60 (2006).
43. The CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).Lancet 348, 1329-1339 (1996).
44. Bhatt, D. L. et al. for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354, 1706-1717 (2006).
45. Bhatt, D. L. et al. for the CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J. Am. Coll. Cardiol. 49, 1982-1988 (2007). (Pubitemid 46694290)
46. Wiviott, S. D. et al. for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007). (Pubitemid 350106708)
47. Bhatt, D. L. Prasugrel in clinical practice. N. Engl. J. Med. 361, 940-942 (2009).
48. Morrow, D. A. et al. for the TRA 2̊ P-TIMI 50 Investigators. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am. Heart. J. 158, 335-341e3 (2009).
49. Becker, R. C. et al. for the TRA-PCI Investigators. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373, 919-928 (2009).
50. Anand, S. et al. for the Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N. Engl. J. Med. 357, 217-227 (2007). (Pubitemid 47080386)
51. Hamburg, N. M. & Balady, G. J. Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits. Circulation 123, 87-97 (2011).
52. Watson, L., Ellis, B. & Leng, G. C. Exercise for intermittent claudication. Cochrane Database of Systematic Reviews, Issue 4 Art. No.: CD000990 doi:101002/14651858CD000990pub2 (2008).
53. Dawson, D. L., Cutler, B. S., Meissner, M. H. & Strandness, D. E. Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 98, 678-686 (1998). (Pubitemid 28387495)
54. Money, S. R. et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J. Vasc. Surg. 27, 267-274 (1998).
55. Lundgren, F., Dahllöf, A. G., Lundholm, K., Schersten, T. & Volkmann, R. Intermittent claudication-surgical reconstruction or physical training? A prospective randomized trial of treatment efficiency. Ann. Surg. 209, 346-355 (1989). (Pubitemid 19083504)
56. Creasy, T. S., McMillan, P. J., Fletcher, E. W., Collin, J. & Morris, P. J. Is percutaneous transluminal angioplasty better than exercise for claudication? Preliminary results from a prospective randomised trial. Eur. J. Vasc. Surg. 4, 135-140 (1990). (Pubitemid 20172197)
57. Gardner, A. W. & Poehlman, E. T. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 274, 975-980 (1995).
58. Bendermacher, B. L., Willigendael, E. M., Teijink, J. A. & Prins, M. H. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database of Systematic Reviews, Issue 2 Art. No.: CD005263 doi:101002/14651858CD005263pub2 (2006).
59. White, C. Clinical practice. Intermittent claudication. N. Engl. J. Med. 356, 1241-1250 (2007).
60. Gray, B. H. et al. for the AHA Writing Group 7 Atherosclerotic Peripheral Vascular Disease Symposium II: lower-extremity revascularization: state of the art. Circulation 118, 2864-2872 (2008).
61. White, C. J. & Gray, W. A. Endovascular therapies for peripheral arterial disease: an evidence-based review. Circulation 116, 2203-2215 (2007). (Pubitemid 350060358)
62. Bronas, U. G. et al. for the CLEVER Research Group. Design of the multicenter standardized supervised exercise training intervention for the claudication: exercise vs endoluminal revascularization (CLEVER) study. Vasc. Med. 14, 313-321 (2009).
63. Rao, K. M., Simel, D. L., Cohen, H. J., Crawford, J. & Currie, M. S. Effects of pentoxifylline administration on blood viscosity and leukocyte cytoskeletal function in patients with intermittent claudication. J. Lab. Clin. Med. 115, 738-744 (1990). (Pubitemid 20213165)
64. Franzini, E., Sellak, H., Babin-Chevaye, C., Hakim, J. & Pasquier, C. Effects of pentoxifylline on the adherence of polymorphonuclear neutrophils to oxidant-stimulated human endothelial cells: involvement of cyclic AMP. J. Cardiovasc. Pharmacol. 25 (Suppl. 2), S92-S95 (1995). (Pubitemid 26084660)
65. Kohda, N. et al. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb. Res. 96, 261-268 (1999).
66. Reilly, M. P. & Mohler, E. R. 3rd Cilostazol: treatment of intermittent claudication. Ann. Pharmacother. 35, 48-56 (2001). (Pubitemid 32216282)
67. Beebe, H. G. et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch. Intern. Med. 159, 2041-2050 (1999). (Pubitemid 29453592)
68. Thompson, P. D., Zimet, R., Forbes, W. P. & Zhang, P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am. J. Cardiol. 90, 1314-1319 (2002). (Pubitemid 35449476)
69. Dawson, D. L. et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am. J. Med. 109, 523-530 (2000).
70. Hiatt, W. R., Money, S. R. & Brass, E. P. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).J. Vasc. Surg. 47, 330-336 (2008).
71. Pratt, C. M. Analysis of the cilostazol safety database. Am. J. Cardiol. 87, 28D-33D (2001).
72. Nony, P. et al. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur. J. Clin. Pharmacol. 46, 191-196 (1994). (Pubitemid 24137425)
73. Iida, O. et al. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J. Vasc. Surg. 48, 144-149 (2008).
74. Soga, Y. et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J. Am. Coll. Cardiol. 53, 48-53 (2009).
75. Olin, J. W. & Sealove, B. A. Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin. Proc. 85, 678-692 (2010).
76. Kalish, J. & Hamdan, A. Management of diabetic foot problems. J. Vasc. Surg. 51, 476-486 (2010).
77. Pomposelli, F. B. et al. A decade of experience with dorsalis pedis artery bypass: analysis of outcome in more than 1,000 cases. J. Vasc. Surg. 37, 307-315 (2003). (Pubitemid 36236907)
78. Conte, M. S. et al. for the PREVENT III Investigators. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J. Vasc. Surg. 43, 742-751 (2006).
79. Goshima, K. R., Mills, J. L., Sr & Hughes, J. D. A new look at outcomes after infrainguinal bypass surgery: traditional reporting standards systematically underestimate the expenditure of effort required to attain limb salvage. J. Vasc. Surg. 39, 330-335 (2004). (Pubitemid 38174314)
80. Löfberg, A. M. et al. The use of below-knee percutaneous transluminal angioplasty in arterial occlusive disease causing chronic critical limb ischemia. Cardiovasc. Intervent. Radiol. 19, 317-322 (1996).
81. DeRubertis, B. G. et al. Percutaneous intervention for infrainguinal occlusive disease in women: equivalent outcomes despite increased severity of disease compared with men. J. Vasc. Surg. 48, 150-157 (2008).
82. Lawrence, P. F. & Chandra, A. When should open surgery be the initial option for critical limb ischaemia? Eur. J. Vasc. Endovasc. Surg. 39 (Suppl. 1), S32-S37 (2010).
83. Vorwerk, D., Gunther, R. W., Schurmann, K. & Wendt, G. Aortic and iliac stenoses: follow-up results of stent placement after insufficient balloon angioplasty in 118 cases. Radiology 198, 45-48 (1996). (Pubitemid 26008238)
84. Park, K. B. et al. Stent placement for chronic iliac arterial occlusive disease: the results of 10 years experience in a single institution. Korean J. Radiol. 6, 256-266 (2005).
85. Murphy, T. P. et al. Aortoiliac insufficiency: long-term experience with stent placement for treatment. Radiology 231, 243-249 (2004). (Pubitemid 38379646)
86. Leville, C. D. et al. Endovascular management of iliac artery occlusions: extending treatment to TransAtlantic Inter-Society Consensus class C and D patients. J. Vasc. Surg. 43, 32-39 (2006). (Pubitemid 43083505)
87. Bosch, J. L. & Hunink, M. G. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology 204, 87-96 (1997). (Pubitemid 27281713)
88. Tetteroo, E. et al. Intraarterial pressure gradients after randomized angioplasty or stenting of iliac artery lesions. Dutch Iliac Stent Trial Study Group. Cardiovasc. Intervent. Radiol. 19, 411-417 (1996). (Pubitemid 26422698)
89. Klein, W. M., van der Graaf, Y., Seegers, J., Moll, F. L. & Mali, W. P. Long-term cardiovascular morbidity, mortality, and reintervention after endovascular treatment in patients with iliac artery disease: The Dutch Iliac Stent Trial Study. Radiology 232, 491-498 (2004). (Pubitemid 38971291)
90. Mukherjee, D. & Inahara, T. Endarterectomy as the procedure of choice for atherosclerotic occlusive lesions of the common femoral artery. Am. J. Surg. 157, 498-500 (1989). (Pubitemid 19127467)
91. Springhorn, M. E., Kinney, M., Littooy, F. N., Saletta, C. & Greisler, H. P. Inflow atherosclerotic disease localized to the common femoral artery: treatment and outcome. Ann. Vasc. Surg. 5, 234-240 (1991).
92. Silva, J. A. et al. Percutaneous revascularization of the common femoral artery for limb ischemia. Catheter. Cardiovasc. Interv. 62, 230-233 (2004). (Pubitemid 38788704)
93. Mahmud, E., Keramati, S., Salami, A., Palakodeti, V. & Tsimikas, S. Expanded applications of rotational atherectomy in contemporary coronary and peripheral interventional practice. J. Invasive Cardiol. 17, 207-210 (2005). (Pubitemid 40489483)
94. Fowkes, F. G. et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int. J. Epidemiol. 20, 384-392 (1991).
95. Capek, P., McLean, G. K. & Berkowitz, H. D. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation 83, I70-I80 (1991).
96. Johnston, K. W. Femoral and popliteal arteries: reanalysis of results of balloon angioplasty. Radiology 183, 767-771 (1992).
97. Murray, R. R. Jr. et al. Long-segment femoropopliteal stenoses: is angioplasty a boon or a bust? Radiology 162, 473-476 (1987). (Pubitemid 17015657)
98. Gray, B. H. & Olin, J. W. Limitations of percutaneous transluminal angioplasty with stenting for femoropopliteal arterial occlusive disease. Semin. Vasc. Surg. 10, 8-16 (1997). (Pubitemid 27108233)
99. Krankenberg, H. et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST).Circulation 116, 285-292 (2007). (Pubitemid 47196564)
100. Schillinger, M. et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N. Engl. J. Med. 354, 1879-1888 (2006). (Pubitemid 43872689)
101. Schillinger, M. et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 115, 2745-2749 (2007). (Pubitemid 46842791)
102. Laird, J. R. et al. for the RESILIENT Investigators. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ. Cardiovasc. Interv. 3, 267-276 (2010).
103. Scheinert, D. et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J. Am. Coll. Cardiol. 45, 312-315 (2005). (Pubitemid 40094743)
104. Duda, S. H. et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J. Endovasc. Ther. 13, 701-710 (2006). (Pubitemid 44907633)
105. Tepe, G. et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N. Engl. J. Med. 358, 689-699 (2008). (Pubitemid 351240748)
106. Dake, MD. The Zilver PTX trial. Presented at the 2010 Transcatheter Cardiovascular Therapeutics Congress.
107. Oliva, V. L. & Soulez, G. Sirolimus-eluting stents versus the superficial femoral artery: second round. J. Vasc. Interv. Radiol. 16, 313-315 (2005). (Pubitemid 40354847)
108. Duda, S. H. et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J. Vasc. Interv. Radiol. 16, 331-338 (2005). (Pubitemid 40354849)
109. Lammer, J. Superficial femoral artery Treatment with Drug-Eluting Stents (STRIDES) trial. Presented at the 2009 Cardiovascular and Interventional Radiological Society of Europe Congress.
110. Krepel, V. M., van Andel, G. J., van Erp, W. F. & Breslau, P. J. Percutaneous transluminal angioplasty of the femoropopliteal artery: initial and long-term results. Radiology 156, 325-328 (1985). (Pubitemid 15029756)
111. Dorros, G., Lewin, R. F., Jamnadas, P. & Mathiak, L. M. Below-the-knee angioplasty: tibioperoneal vessels, the acute outcome. Cathet. Cardiovasc. Diagn. 19, 170-178 (1990). (Pubitemid 20150129)
112. Söder, H. K. et al. Prospective trial of infrapopliteal artery balloon angioplasty for critical limb ischemia: angiographic and clinical results. J. Vasc. Interv. Radiol. 11, 1021-1031 (2000).
113. Rastogi, S. & Stavropoulos, S. W. Infrapopliteal angioplasty. Tech. Vasc. Interv. Radiol. 7, 33-39 (2004). (Pubitemid 38881311)
114. Rand, T. et al. PTA versus carbofilm-coated stents in infrapopliteal arteries: pilot study. Cardiovasc. Intervent. Radiol. 29, 29-38 (2006). (Pubitemid 43128136)
115. Siablis, D. et al. Sirolimus-eluting versus bare stents for bailout after suboptimal infrapopliteal angioplasty for critical limb ischemia: 6-month angiographic results from a nonrandomized prospective single-center study. J. Endovasc. Ther. 12, 685-695 (2005). (Pubitemid 43100926)
116. Stein, P. D., Dalen, J. E., Goldman, S. & Theroux, P. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Chest 119, 278S-282S (2001). (Pubitemid 32154205)
117. Tangelder, M. J., Lawson, J. A., Algra, A. & Eikelboom, B. C. Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. J. Vasc. Surg. 30, 701-709 (1999). (Pubitemid 29487563)
118. Belch, J. J. et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J. Vasc. Surg. 52, 825-833 (2010).
119. Wixon, C. L., Mills, J. L., Westerband, A., Hughes, J. D. & Ihnat, D. M. An economic appraisal of lower extremity bypass graft maintenance. J. Vasc. Surg. 32, 1-12 (2000). (Pubitemid 30461148)
120. Donaldson, M. C., Mannick, J. A. & Whittemore, A. D. Causes of primary graft failure after in situ saphenous vein bypass grafting. J. Vasc. Surg. 15, 113-118 (1992).
121. Bergamini, T. M., Towne, J. B., Bandyk, D. F., Seabrook, G. R. & Schmitt, D. D. Experience with in situ saphenous vein bypasses during 1981 to 1989: determinant factors of long-term patency. J. Vasc. Surg. 13, 137-147 (1991).
122. Mills, J. L. Sr. et al. The natural history of intermediate and critical vein graft stenosis: recommendations for continued surveillance or repair. J. Vasc. Surg. 33, 273-278 (2001).
123. Armstrong, P. A. et al. Optimizing infrainguinal arm vein bypass patency with duplex ultrasound surveillance and endovascular therapy. J. Vasc. Surg. 40, 724-730 (2004).
124. Soga, Y. et al. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc. Surg. 52, 608-615 (2010).
125. Baril, D. T. et al. Outcomes of endovascular interventions for TASC II B and C femoropopliteal lesions. J. Vasc. Surg. 48, 627-633 (2008).
126. Baril, D. T. et al. Endovascular interventions for TASC II D femoropopliteal lesions. J. Vasc. Surg. 51, 1406-1412 (2010).